+Compare
FENC
Stock ticker: NASDAQ
AS OF
Loading...
Price
Loading...
Change
Loading...
Capitalization
224.32M

FENC Fennec Pharmaceuticals Forecast, Technical & Fundamental Analysis

a developer of therapeutic products based on cell adhesion

Industry Biotechnology
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
A.I.Advisor
a Summary for FENC with price predictions
07:00 PM EST Dec 03, 2023

Aroon Indicator for FENC shows an upward move is likely

FENC's Aroon Indicator triggered a bullish signal on December 04, 2023. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 193 similar instances where the Aroon Indicator showed a similar pattern. In of the 193 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on November 02, 2023. You may want to consider a long position or call options on FENC as a result. In of 107 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

FENC moved above its 50-day moving average on November 06, 2023 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for FENC crossed bullishly above the 50-day moving average on November 10, 2023. This indicates that the trend has shifted higher and could be considered a buy signal. In of 13 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where FENC advanced for three days, in of 287 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The RSI Oscillator demonstrated that the stock has entered the overbought zone. This may point to a price pull-back soon.

The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.

FENC broke above its upper Bollinger Band on December 04, 2023. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

Fear & Greed

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. FENC’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. FENC’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock better than average.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (78.125) is normal, around the industry mean (20.645). P/E Ratio (0.000) is within average values for comparable stocks, (137.286). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (7.704). Dividend Yield (0.000) settles around the average of (0.035) among similar stocks. P/S Ratio (17.391) is also within normal values, averaging (329.397).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Regeneron Pharmaceuticals (NASDAQ:REGN), Moderna (NASDAQ:MRNA), Incyte Corp (NASDAQ:INCY), Sarepta Therapeutics (NASDAQ:SRPT), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), BioCryst Pharmaceuticals (NASDAQ:BCRX), Novavax (NASDAQ:NVAX), Adaptive Biotechnologies Corp (NASDAQ:ADPT), Sorrento Therapeutics (OTC:SRNEQ).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.29B. The market cap for tickers in the group ranges from 402 to 464.61B. NVO holds the highest valuation in this group at 464.61B. The lowest valued company is PNEXF at 402.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was 6%. For the same Industry, the average monthly price growth was 26%, and the average quarterly price growth was 26%. MMIRF experienced the highest price growth at 247%, while BRRGF experienced the biggest fall at -99%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was -31%. For the same stocks of the Industry, the average monthly volume growth was -48% and the average quarterly volume growth was -15%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 85
Price Growth Rating: 62
SMR Rating: 94
Profit Risk Rating: 95
Seasonality Score: 26 (-100 ... +100)
View a ticker or compare two or three
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
Ad is loading...
A.I. Advisor
published Earnings

FENC is expected to report earnings to fall 66.71% to -2 cents per share on March 27

Fennec Pharmaceuticals FENC Stock Earnings Reports
Q4'23
Est.
$-0.02
Q3'23
Beat
by $0.04
Q2'23
Missed
by $0.05
Q1'23
Missed
by $0.02
Q4'22
Est.
$-0.26
The last earnings report on November 06 showed earnings per share of -7 cents, beating the estimate of -10 cents. With 143.22K shares outstanding, the current market capitalization sits at 224.32M.
A.I. Advisor
published General Information

General Information

a developer of therapeutic products based on cell adhesion

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
68 TW Alexander Drive
Phone
+1 919 636-4530
Employees
36
Web
https://www.fennecpharma.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
RYFIX74.31N/A
N/A
Rydex Financial Services Inv
AGFRX96.70N/A
N/A
AB Growth R
SUTCX17.31N/A
N/A
AB Sustainable US Thematic C
ESPIX39.10N/A
N/A
Allspring Special Small Cap Value Adm
WFLLX16.85N/A
N/A
Allspring Large Cap Core Admin

FENC and

Correlation & Price change

A.I.dvisor tells us that FENC and INKT have been poorly correlated (+28% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that FENC and INKT's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To FENC
1D Price
Change %
FENC100%
+6.24%
INKT - FENC
28%
Poorly correlated
+1.92%
KRRO - FENC
27%
Poorly correlated
+18.37%
AURA - FENC
26%
Poorly correlated
+1.83%
AUPH - FENC
26%
Poorly correlated
-2.65%
THRX - FENC
25%
Poorly correlated
N/A
More

Groups containing FENC

Correlation & Price change

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To FENC
1D Price
Change %
FENC100%
+6.24%
cells
(undefined stocks)
31%
Poorly correlated
+3.98%
drugs
(undefined stocks)
21%
Poorly correlated
+1.61%
biotechnology
(undefined stocks)
20%
Poorly correlated
+1.96%
therapeutics
(undefined stocks)
17%
Poorly correlated
+3.03%